These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Cardiovascular diseases in peritoneal dialysis patients: the size of the problem. Lameire N; Vanholder RC; Van Loo A; Lambert MC; Vijt D; Van Bockstaele L; Vogeleere P; Ringoir SM Kidney Int Suppl; 1996 Nov; 56():S28-36. PubMed ID: 8914051 [No Abstract] [Full Text] [Related]
27. [Dialysis modality and cardiac disease in chronic kidney insufficiency]. Grzegorzewska AE Pol Merkur Lekarski; 2006 Apr; 20(118):453-6. PubMed ID: 16886575 [TBL] [Abstract][Full Text] [Related]
28. Hematological changes post-hemo and peritoneal dialysis among renal failure patients in Sudan. Mohamed Ali MS; Babiker MA; Merghani LB; Ali FA; Abdulmajeed MH Saudi J Kidney Dis Transpl; 2008 Mar; 19(2):274-9. PubMed ID: 18310883 [TBL] [Abstract][Full Text] [Related]
29. The effect of dialysis modality (PD and HD) on cardiac morphology and functions in chronic kidney disease patients at very high cardiovascular risk. Krajewska M; Kosmala W; Weyde W; Madziarska K; Porazko T; Kopec W; Klak R; Penar J; Kusztal M; Watorek E; Golebiowski T; Klinger M Nephrol Dial Transplant; 2008 Feb; 23(2):768-9. PubMed ID: 18029367 [No Abstract] [Full Text] [Related]
30. Predictive role of BNP and NT-proBNP in hemodialysis patients. Sun L; Sun Y; Zhao X; Xu C; Chen D; Li L; Ma Y; Rong S; Mei C Nephron Clin Pract; 2008; 110(3):c178-84. PubMed ID: 18957868 [TBL] [Abstract][Full Text] [Related]
31. Lipid abnormalities and cardiovascular risk in renal disease. Ritz E; Wanner C J Am Soc Nephrol; 2008 Jun; 19(6):1065-70. PubMed ID: 18369085 [TBL] [Abstract][Full Text] [Related]
32. [Peritoneal dialysis. Modalities and indications]. Faller B Soins; 1997 Dec; (621):8-10. PubMed ID: 9479212 [No Abstract] [Full Text] [Related]
33. [Psycho-visceral markers of cardiovascular pathology development in servicemen]. Kodochigova AI; Kirichuk VF; Demina TM Voen Med Zh; 2002 Sep; 323(9):33-8, 96. PubMed ID: 12449752 [TBL] [Abstract][Full Text] [Related]
34. Potential benefits of renal diets on cardiovascular risk factors in chronic kidney disease patients. Cupisti A; Aparicio M; Barsotti G Ren Fail; 2007; 29(5):529-34. PubMed ID: 17654313 [TBL] [Abstract][Full Text] [Related]
35. Association of plasma adiponectin and cardiovascular risk profiles in nondiabetic uremic patients on peritoneal dialysis. Tsao YT; Hsu YJ; Chu NF; Lai CH; Chiu JS; Lin SH J Nephrol; 2008; 21(5):744-52. PubMed ID: 18949730 [TBL] [Abstract][Full Text] [Related]
36. The effect of dialytic modalities on clinical outcomes in ESRD patients with familial Mediterranean fever. Sahin S; Sahin GM; Ergin H; Kantarci G Ren Fail; 2007; 29(3):315-9. PubMed ID: 17497446 [TBL] [Abstract][Full Text] [Related]
37. [Why is peritoneal dialysis used more in Finland?]. Mäkelä S; Saha H Duodecim; 2003; 119(18):1709-11. PubMed ID: 14587456 [No Abstract] [Full Text] [Related]
38. [Role of biomarkers for risk stratification in the prevention of cardiovascular diseases]. Sinning C; Keller T; Blankenberg S Dtsch Med Wochenschr; 2009 Oct; 134(40):2019-22. PubMed ID: 19777420 [No Abstract] [Full Text] [Related]
39. Biomarkers for cardiovascular disease: challenges and future directions. May A; Wang TJ Trends Mol Med; 2008 Jun; 14(6):261-7. PubMed ID: 18487087 [TBL] [Abstract][Full Text] [Related]
40. Markers of malign across the cardiovascular continuum: interpretation and application. Dzau VJ Circulation; 2004 Jun; 109(25 Suppl 1):IV1-2. PubMed ID: 15226244 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]